Finally, this work demonstrated that lncRNA XIST alleviates hepatic IR via regulating the miR‐182‐5p/IGF‐1R axis, which could be the promising therapeutic target of IR‐related diseases such as T2D and metabolic syndrome. This evidence concerns the gene XIST and metabolic syndrome.